Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Pamidronate was given to 10 patients with end stage renal failure who had become symptomatically hypercalcaemic due to the use of calcium based phosphate binders and alphacalcidol. All patients were initially treated with rehydration, increased dialysis and withdrawal of drugs, however despite this they remained symptomatic and the serum calcium remained elevated, mean 3.89 mmol/l (range 3.44-4.74). Pamidronate was given, and the serum calcium had declined to 2.92 mmol/l (2.79-3.84), p < 0.01 by the third day. The reduction in serum calcium observed with pamidronate was more rapid than that in 9 patients who developed asymptomatic hypercalcaemia, mean serum calcium 3.45 mmol/l (3.4-3.56), with an actual median reduction of 0.72 mmol/l (0.37-1.30) in the pamidronate group after 3 days compared to 0.20 mmol/l (0.10-0.52) in the conservatively treated asymptomatic group, p < 0.01, and a median percentage decrease of 19% (10-30) in the pamidronate group and 6% (3-15) in the asymptomatic group, p < 0.01. In this study pamidronate was a safe and effective agent in reducing serum calcium in a group of hypercalcaemic dialysis patients.
Davenport
A
A
Department of Renal Medicine, Southmead Hospital, Bristol, England.
Goel
S
S
Mackenzie
J C
JC
D002119:Calcium Carbonate / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate; D010531:Peritoneal Dialysis, Continuous Ambulatory; D006435:Renal Dialysis
D004164:Diphosphonates; D006887:Hydroxycholecalciferols; D002119:Calcium Carbonate; D000077268:Pamidronate; C008088:alfacalcidol